FDA to alter biosimilar ‘suffix’ policy

The US Food and Drug Administration (FDA) yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

21 August 2026 Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.

Biotech

10x Genomics dealt major blow in sequencing fight

20 August 2026 Three disputed sequencing patents took the spotlight as the Federal Circuit weighed challenges to a trio of PTAB rulings.

Pharma

SK Biopharmaceuticals settles epilepsy generic dispute

20 August 2026 A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.

More features

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

10x Genomics dealt major blow in sequencing fight

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

Abbott fends off Chinese rival’s patent challenge at UPC

Former head of litigation at Nokia returns to Bird & Bird

Former USPTO acting director takes the helm at C4IP

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

FDA to alter biosimilar ‘suffix’ policy

More on this story

Editor's picks

Editor's picks

More features